Disclosures: Inbal Houri: Nothing to Disclose, Claire Gage: Nothing to Disclose, Hooman Ebrahimi: Nothing to Disclose, Vathany Kulasingam: Nothing to Disclose, Guilherme Cancado: Nothing to Disclose, Kristel Leung: Nothing to Disclose, Bettina Hansen: Nothing to Disclose, Aliya Gulamhusein: Nothing to Disclose, Gideon Hirschfield: Intercept: Consultant, GSK: Consultant, CymaBay: Consultant, Ipsen: Consultant, Falk: Consultant, Pliant: Consultant, Morphogen: Consultant, Roche: Consultant, Mirum: Consultant, Advanz: Consultant, Chemomab: Consultant, Gilead: Consultant, Kowa: Consultant 2451 ABERRANT CYTOKERATIN 7 EXPRESSION BY HEPATOCYTES CAN PREDICT THE DUCTOPENIA GRADE IN PRIMARY BILIARY CHOLANGITIS Hongli Liu 1 Qing-Fang Xiong 1 yandan zhong 1 Du-Xian Liu 1 Ping Huang 1 Xiao-Ning Feng 1 Yu Zhang 2 Yong-Feng Yang 1 , 1 The Second Hospital of Nanjing, Teaching Hospital of Southeast University, 2 The Second Hospital of Nanjing, Teaching Hospital of Southeast University, Background: Aberrant cytokeratin 7 expression by hepatocytes (CK7+Hs) is the hallmark characteristic of cholestasis diseases, especially in ductopenia diseases such as primary biliary cholangitis (PBC)
Your body needs both iron and folic acid to produce hemoglobin efficiently
As such, the isoxazole Cn Acs1 inhibitors also provide proof-of-principle for inhibition of fungal Acs as an antifungal strategy even in species that can generate AcCoA through ATP-citrate lyases
November 27, 2017
Jul 2018;275(7):1697-1707
